By Kuldip K. Ambastha
The stock of BeiGene, Ltd. (BGNE), a commercial stage biopharmaceutical company focused on cancer treatment drugs, saw a +20.5% increase in price per share on Wednesday, October 12, 2022. Brukinsa (zanubrutinib) in its Phase 3 trial data showed highly positive results in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), in an independent review. The drug was well-tolerated in patients, and showed superior progression-free survival (PFS) in individuals compared to rival drugs already available to patients. The European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA’s CHMP) has issued a positive opinion on Brukinsa. If the relevant regulatory agencies eventually issue final approvals for the use of Brukinsa in people around the world, BeiGene may have a bright future.
Keywords – BeiGene, Ltd., BeiGene, BGNE, Brukinsa, zanubrutinib, biopharmaceutical, cancer, treatment, drug, Phase 3, trial, chronic lymphocytic leukemia, CLL, small lymphocytic lymphoma, SLL, progression-free survival, PFS, European Medicines Agency, EMA, Committee for Medicinal Products for Human Use, CHMP, regulation, approval.
Disclosure – The principals and clients of Ambastha Financial LLC have no positions in BGNE.
Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2022 – Ambastha Financial LLC.
CONTACT US